NCT00335374

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 202 (actual)
• Sponsor: Solvay Pharmaceuticals · Industry
• Sex: All
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial

Conditions

• Early Stage Parkinson's Disease

Interventions

Type	Name	Description
DRUG	Pardoprunox	12 -42 mg

Timeline

• Start date: 2007-08-01
• Primary completion: 2008-09-01
• Completion: 2008-11-01
• First posted: 2006-06-09
• Last updated: 2009-02-06

Locations

75 sites across 15 countries: United States, Australia, Czechia, Estonia, Germany, India, Italy, Lithuania, Malaysia, Netherlands, Poland, Portugal, South Africa, Taiwan, Thailand